News

CF Drug Developer N30 Pharmaceuticals Is Now Nivalis Therapeutics

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm committed to developing product candidates to address cystic fibrosis (CF), recently announced that the company has changed its name to Nivalis Therapeutics, Inc. Nivalis Therapeutics’ lead product candidate is N91115, a new inhibitor of S-nitrosoglutathione reductase (GSNOR) for the treatment of CF. The company’s new name, Nivalis…

Enterprise Therapeutics Raises $2.4M To Fund Novel CF Therapy

Drug discovery company Enterprise Therapeutics Ltd. has successfully raised $2.4 million through a Series-A financing round. The company, based at the University of Sussex in the United Kingdom, is focused on creating novel therapies for respiratory diseases, such as cystic fibrosis (CF). A portion the funding will be invested in the…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.